- Home
- KGS vs MLTX Comparison
KGS vs MLTX Comparison
Compare KGS & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGS
- MLTX
- Stock Information
- Founded
- KGS 2011
- MLTX 2021
- Country
- KGS United States
- MLTX Switzerland
- Employees
- KGS N/A
- MLTX N/A
- Industry
- KGS
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- KGS
- MLTX Health Care
- Exchange
- KGS Nasdaq
- MLTX Nasdaq
- Market Cap
- KGS 3.8B
- MLTX 2.3B
- IPO Year
- KGS 2023
- MLTX N/A
- Fundamental
- Price
- KGS $34.88
- MLTX $39.42
- Analyst Decision
- KGS Strong Buy
- MLTX Strong Buy
- Analyst Count
- KGS 11
- MLTX 8
- Target Price
- KGS $41.00
- MLTX $80.50
- AVG Volume (30 Days)
- KGS 1.2M
- MLTX 436.0K
- Earning Date
- KGS 05-07-2025
- MLTX 05-06-2025
- Dividend Yield
- KGS 4.71%
- MLTX N/A
- EPS Growth
- KGS 94.67
- MLTX N/A
- EPS
- KGS 0.56
- MLTX N/A
- Revenue
- KGS $1,159,311,000.00
- MLTX N/A
- Revenue This Year
- KGS $18.26
- MLTX $103.42
- Revenue Next Year
- KGS $8.02
- MLTX N/A
- P/E Ratio
- KGS $61.68
- MLTX N/A
- Revenue Growth
- KGS 36.33
- MLTX N/A
- 52 Week Low
- KGS $24.84
- MLTX $31.42
- 52 Week High
- KGS $50.43
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- KGS 49.25
- MLTX 54.48
- Support Level
- KGS $32.45
- MLTX $31.90
- Resistance Level
- KGS $35.04
- MLTX $40.97
- Average True Range (ATR)
- KGS 1.93
- MLTX 2.55
- MACD
- KGS 0.41
- MLTX 0.58
- Stochastic Oscillator
- KGS 93.37
- MLTX 83.77
About KGS Kodiak Gas Services Inc.
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Compression Operations and Other Services. Compression Operations consist of operating company-owned and customer-owned compression infrastructure for customers, pursuant to fixed-revenue contracts to enable the production, gathering and transportation of natural gas and oil. Other Services consist of a full range of contract services to support the needs of customers, including station construction, maintenance and overhaul and other ancillary time and material-based offerings.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.